投資者係列:遠程醫療市場的機會
市場調查報告書
商品編碼
1056812

投資者係列:遠程醫療市場的機會

Investor Series: Opportunities in the Telehealth Market - Focus on [A] Need for Telehealth Solutions / Services, [B] Landscape of Key Innovators, [C] Analysis of Product Offerings and Affiliated Value

出版日期: | 出版商: Roots Analysis | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告提供遠程醫療行業的詳細信息,涵蓋核心產品、外圍產品和相關服務。本報告從技術和財務角度,從有前途的商業企業的角度,著眼於未來十年該領域的機遇將如何變化。

目錄

Excel 可交付成果

第 1 章主要創新者數據集

  • 摘要儀表板
  • 關鍵創新者數據集
  • 遠程醫療產品數據集
  • 企業健康指標
  • 價值主張分析
  • 企業競爭力分析
  • 主要收購目標

第二章融資與企業價值分析

  • 摘要儀表板
  • 對遠程醫療的資本投資
  • 企業評價分析

第3章基本和技術財務分析

  • 摘要儀表板
  • 業務風險分析

第四章主要投資者退出機會分析與映射

  • 摘要儀表板
  • 市場預測和機會分析
  • 主要投資者退出分析

PowerPoint 可交付成果

第一章上下文

第2章項目方法

第三章項目目的

第 4 章執行摘要

第一節:遠程醫療解決方案和關鍵創新者情況

第五章現代遠程醫療市場

  • 需要遠程醫療解決方案/服務
  • 行業專家觀點
  • 遠程醫療的主要舉措(案例研究)
  • 近期會議分析

第 6 章主要創新者市場情況

  • 概覽
  • 領先的遠程醫療創新者
  • 結束語

第七章主要產品情況

  • 概覽
  • 遠程醫療產品及相關服務
  • 結束語

第 8 章索引公司穩健性和分析價值建議

  • 概覽
  • 企業健康指標
  • 價值主張分析
  • 企業競爭力分析
  • 結束語

第二節:投資與企業價值分析

第九章融資與投資分析

  • 2011-2021 年融資活動概覽

第十章企業評價分析

  • 概覽
  • 評價分析
  • 結論

第三節:基本和技術財務分析

第11章公共風險投資的財務分析

  • 概覽
  • 23andMe
  • 榮譽
  • 安威爾
  • 對話
  • 談話空間
  • Teladoc 健康

第四節:業務風險分析

第十二章上市公司風險分析

  • 概覽
  • 業務風險分析
  • 結束語

第五節:機會分析和關鍵投資者退出映射

第13章市場預測和機會分析

  • 概述與研究方法
  • 2021-2035 年整體遠程醫療市場規模

第14章投資者退出和預計投資回報

  • 投資者展望
  • 已發佈投資者退出
    • 預計投資回報
  • 結束語

第15章主要收購目標

  • 概覽
  • 主要收購目標分析
  • 結束語

第16章附錄一:表格數據

第十七章附錄二:公司和組織名單

簡介目錄

Title:
Investor Series: Opportunities in the Telehealth Market
Focus on [A] Need for Telehealth Solutions / Services, [B] Landscape of Key Innovators, [C] Analysis of Product Offerings and Affiliated Value Propositions, [D] Insights from Historical Funding Activity, [E] Startup Health Indexing and Company Valuation Analysis, [F] Financial Analysis of Key Public Ventures, [G] Market Forecast and Opportunity Analysis, [H] Insights from Publicly Disclosed Investor Exits and [I] Key Acquisition Targets.

Example Insights:

We focused on the efforts of the early-stage/mid-sized ventures, and their multiplicity of products/solutions that enable remote access to healthcare; innovation in this field is deemed to have just begun.

Overview

Telehealth refers to the remote delivery of healthcare services, such as medical consults, examination / interpretation of medical reports, critical health parameter monitoring, medical information sharing (between physicians and their patients) and patient education, using modern telecommunications solutions. In other words, it offers a convenient and cost-effective way for individuals with health problems to seek medical attention from the comfort of their respective homes. Currently, a wide variety of virtual conferencing tools and intuitive software are available for the aforementioned purposes. In fact, during the COVID-19 pandemic, due to the enforcement of mandatory social distancing practices, a lot of routine and emergency medical consultations were reported to have been conducted in the virtual environment. In 2020, it was estimated that 76% of hospitals in the US were using diverse telehealth technologies to connect doctors to patients. Although the demand for and use of telehealth technologies witnessed a notable surge (experts believe that the use of such solutions increased by around 40% compared to the pre-COVID era) during the recent pandemic, the idea of remote delivery of medical advice / information is believed to have been conceived much earlier. It is, therefore, safe to infer that the pandemic served to provide a much-needed impetus to drive the adoption of remote medical services. Moreover, even as social distancing mandates are being revoked across the world, the expanded access to quality healthcare offered by telemedicine is anticipated to continue to be used at a less unprecedented but evident scale.

The recent years have witnessed a surge in investment activity in companies involved in the development of telehealth solutions. This was primarily fueled by the demand for remote healthcare services, which led to a marked increase in the adoption of various telemedicine, health tracking and medical information sharing products. According to one of our recent studies, many companies are also engaged in providing tailored solutions, along with remote access to medical care facilities to patients. In addition, around 90% of the healthcare organizations are believed to have already invested or have revealed strong intentions to invest in remote patient monitoring systems. In the wake of the recent increase in demand, we believe that the market presents lucrative investment opportunities for investors on the lookout for both short- and long-term gains.

Scope of the Report

The "Investor Series: Opportunities in the Telehealth Market" report provides detailed information on the telehealth industry, covering the core and peripheral products and affiliated services. It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of promising business ventures, over the coming decade. The information in this report has been presented across multiple deliverables, featuring interactive MS Excel sheets and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.

The report features the following details:

  • A qualitative perspective on the current need for telehealth solutions and services, highlighting some of the key applications of such offerings and featuring information on the various companies that are engaged in this domain (along with details of some exemplary ventures that have either succeeded or failed in this market) .
  • A detailed analysis of telehealth focused companies that were established on or after 2005, featuring inputs on observed trends related to basic input parameters, such as year of establishment, headquarters, company size, and type of venture.
  • A quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research.
  • An assessment of the various products and affiliated services, offered by the companies mentioned above, featuring analysis based on number and type of product, and an informed perspective on the value of the aforementioned offerings based on multiple relevant aspects, namely applicability and adoption trends, treatment-related value, value to patients, value to patients and healthcare professionals, and others.
  • A company competitiveness analysis, offering a quantitative basis for comparing the diverse telehealth solutions captured in this report, based on the insights generated from the abovementioned analyses.
  • A detailed analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a list of the leading investors in telehealth, based on their participation in financing activity in this domain.
  • A proprietary analysis defining a basis for estimating the relative valuation of the private companies among the key innovators discussed in this report. Estimates presented in the report were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.
  • An elaborate review of the overall telehealth market from a financial perspective, including detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of the publicly listed companies within the key innovators dataset.
  • A business risk analysis, based on some of the major categories of risk that are usually discussed in the industry - namely operations-related risks, overall business-related risks, financial risks, product / technology associated risks, and social, economic, environmental and political risks.
  • Case studies of instances where investors have exited various telehealth-related ventures, offering insights on returns on investment made (based on availability of data) . Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the telehealth market.
  • A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures around which there is likely to be interest (in terms of acquisition potential) .

One of the key objectives of the report was to evaluate the current opportunity and the future potential of the site management organizations market over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035. The opportunity has been segregated on the basis of [A] key market segments (namely telemedicine (which further includes interactive patient care, store & forward telemedicine and remote patient monitoring offerings), patient portals and tele-education) and [B] geography (North America, Europe, Asia Pacific and the rest of the world). To account for future uncertainties in the market and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

DELIVERABLE OUTLINES

Excel Deliverables

Sheet I includes details on the key innovator companies captured in the report along with a summary dashboard, featuring interactive graphical representations of key insights generated from the company health indexing, value proposition analysis and company competitiveness analysis. This sheet also includes details of our proprietary key acquisition targets analysis.

Sheet II features a summary dashboard, including interactive graphical representations of some of the key insights generated related to the capital investments made in telehealth (since 2011) and our proprietary company valuation analysis (focused on the key innovator companies that have not yet gone public) .

Sheet III is a summary of insights generated from a detailed fundamental and technical financial analysis, of publicly listed ventures in the key innovators dataset. It also offers a pictorial perspective on some of the major areas of risk associated with telehealth. It is worth mentioning that for each company, there is a separate MS Excel sheet, which provides information on key financial parameters and competitive insights based on historical and prevalent trends.

Sheet IV is a summary MS Excel dashboard, offering detailed graphical representations of the contemporary and future opportunity associated with telehealth. It also includes a collection of publicly available information on the investments made by select investors in companies that are now publicly listed. Based on the aforementioned information, the sheet offers a proprietary perspective on likely returns on investment received by the mentioned investors.

PowerPoint Deliverable

: Key Section Outlines

Section I describes the current need for telehealth solutions and services, highlighting some of their key application areas. It includes information on the various companies that are engaged in this domain, along with details of some exemplary ventures that have either succeeded or failed in this market. It also features inputs from representatives from key stakeholder companies in this domain (as stated in publicly available articles and interview transcripts) . The section concludes with information on the different conferences that have been conducted in this domain in the recent past.

The section also provides a [A] detailed analysis of telehealth focused innovator companies that were established on or after 2005. The section features basic company related details, such as year of establishment, headquarters, company size, and type of venture. It also includes [B] information on the various products and affiliated services, including analysis based on number and type of product, which are offered by the aforementioned companies. Based on the abovementioned insights, it offers a [C] quantitative perspective on the relative health (based on basic company details, product details, financing activity, and estimated revenues and profits) of the different innovator companies. In addition, it offers an informed perspective on the key [D] value proposition of the same companies based on multiple relevant aspects, namely applicability and adoption trends, treatment-related value, value to patients, value to patients and healthcare professionals, and others. Finally, based on the aforementioned inputs, the section features a detailed [E] company competitiveness analysis, offering a quantitative basis for comparing the diverse telehealth solutions captured in this report. It is worth mentioning that the analysis described in this section is based on proprietary scoring criteria, which was informed via secondary research.

Section II offers insights from a detailed [A] analysis of the funding and investment activity that has taken place in this domain, since 2011. It also includes financing category-wise trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the key innovator companies discussed in the report. Further, it features a proprietary basis for [B] estimating the relative valuation of the private companies among the key innovators discussed in this report. It is worth mentioning that the aforementioned estimations were based on information gathered via secondary research, for a sample set of companies. Key inferences drawn from the sample set were extrapolated using the appropriate mathematical models to generate valuation estimates for all companies in the dataset.

Section III is modelled in the likeness of an equity research report. It features a review of the overall telehealth market from a financial perspective and includes detailed fundamental (insights from the balance sheet, and key financial ratios) and technical analyses (insights from historical and recent stock price variations, and analysis using popular stock performance indicators) of financial data of six of the publicly listed companies within the key innovators dataset.

Section IV includes a business risk analysis, offering insights encompassing several known categories of risk; these include operations-related risks, business-related risks, product / technology risks, financial / asset-related risks, and other risks.

Section V features is an insightful market forecast analysis, highlighting the estimated current and future sizes of overall telehealth market till the year 2035. The opportunity has been segregated on the basis of [A] key market segments (namely telemedicine (which further includes interactive patient care, store & forward telemedicine and remote patient monitoring offerings), patient portals and tele-education) and [B] geography (North America, Europe, Asia Pacific and the rest of the world). It also includes case studies of instances where investors have exited various telehealth-related ventures, offering insights on returns on investment made (based on availability of data) . Based on the abovementioned details, it provided an informed opinion on the future outlook for investors in the telehealth market.

Section VI offers insights from a proprietary analysis that leverages inputs from the startup health indexing and value proposition analysis (described in section I) , to offer qualitative recommendations on companies that are likely to be perceived as key acquisition targets.

Table of Contents

Excel Deliverable

1. Key Innovators Dataset

  • 1.1. Summary Dashboard
  • 1.2. Key Innovators Dataset
  • 1.3. Telehealth Products Dataset
  • 1.4. Company Health Indexing
  • 1.5. Value Proposition Analysis
  • 1.6. Company Competitiveness Analysis
  • 1.7. Key Acquisition Targets

2. Analysis of Funding & Company Valuation

  • 2.1. Summary Dashboard
  • 2.2. Capital Investments in Telehealth
  • 2.3. Company Valuation Analysis

3. Fundamental & Technical Financial Analysis

  • 3.1. Summary Dashboard
  • 3.2. Business Risk Analysis

4. Opportunity Analysis & Mapping Key Investor Exits

  • 4.1. Summary Dashboard
  • 4.2. Market Forecast & Opportunity Analysis
  • 4.3. Analysis of Key Investor Exits

PowerPoint Deliverable

1. Context

2. Project Approach

3. Project Objectives

4. Executive Summary

Section I: Need for Telehealth Solutions & Key Innovators Landscape

5. Contemporary Telehealth Market

  • 5.1. Need for Telehealth Solutions / Services
  • 5.2. Industry Expert Perspective
  • 5.3. Key Initiatives in Telehealth (Case Studies)
    • 5.3.1. Exemplary Business Successes
    • 5.3.2. Exemplary Business Failures
  • 5.4. Analysis of Recent Conferences

6. Key Innovators Market Landscape

  • 6.1. Overview
  • 6.2. Key Innovators in Telehealth
    • 6.2.1. Analysis by Year of Establishment
    • 6.2.2. Analysis by Company Size
    • 6.2.3. Analysis by Type / Stage of Venture
    • 6.2.4. Analysis by Geographical Location
  • 6.3. Concluding Remarks

7. Key Products Landscape

  • 7.1. Overview
  • 7.2. Telehealth Products and Affiliated Services
    • 7.2.1. Analysis by Type of Product
    • 7.2.2. Analysis by
  • 7.3. Concluding Remarks

8. Company Health Indexing and Value Proposition Analysis

  • 8.1. Overview
  • 8.2. Company Health Indexing
  • 8.3. Value Proposition Analysis
  • 8.4. Company Competitiveness Analysis
  • 8.5. Concluding Remarks

Section II: Analysis of Investments & Company Valuation

9. Funding and Investments Analysis

  • 9.1. Overview of Funding Activity, 2011-2021
    • 9.1.1. Analysis by Year of Funding
    • 9.1.2. Analysis by Type of Funding
    • 9.1.3. Analysis by Type of Funding and Amount Invested
    • 9.1.4. Funding and Investments Summary

10. Company Valuation Analysis

  • 10.1. Overview
  • 10.2. Valuation Analysis
    • 10.2.1. Approach 1: Based on Estimated Valuation
    • 10.2.2. Approach 2: Based on Estimated Value and Revenues
    • 10.2.3. Approach 3: Based on Stage of Financing
  • 10.3. Conclusion

Section III: Fundamental & Technical Financial Analysis

11. Financial Analysis of Public Ventures

  • 11.1. Overview
  • 11.2. 23andMe
    • 11.2.1. Fundamental Analysis of Company Financials
      • 11.2.1.1. Insights from Balance Sheet
      • 11.2.1.2. Analysis of Financial Ratios
    • 11.2.2. Technical Analysis of Stock Price
      • 11.2.2.1. Historical Trends
      • 11.2.2.2. Recent Trends
  • 11.3. Accolade
    • 11.3.1. Fundamental Analysis of Company Financials
      • 11.3.1.1. Insights from Balance Sheet
      • 11.3.1.2. Analysis of Financial Ratios
    • 11.3.2. Technical Analysis of Stock Price
      • 11.3.2.1. Historical Trends
      • 11.3.2.2. Recent Trends
  • 11.4. Amwell
    • 11.4.1. Fundamental Analysis of Company Financials
      • 11.4.1.1. Insights from Balance Sheet
      • 11.4.1.2. Analysis of Financial Ratios
    • 11.4.2. Technical Analysis of Stock Price
      • 11.4.2.1. Historical Trends
      • 11.4.2.2. Recent Trends
  • 11.5. Dialogue
    • 11.5.1. Fundamental Analysis of Company Financials
      • 11.5.1.1. Insights from Balance Sheet
      • 11.5.1.2. Analysis of Financial Ratios
    • 11.5.2. Technical Analysis of Stock Price
      • 11.5.2.1. Historical Trends
      • 11.5.2.2. Recent Trends
  • 11.6. Talkspace
    • 11.6.1. Fundamental Analysis of Company Financials
      • 11.6.1.1. Insights from Balance Sheet
      • 11.6.1.2. Analysis of Financial Ratios
    • 11.6.2. Technical Analysis of Stock Price
      • 11.6.2.1. Historical Trends
      • 11.6.2.2. Recent Trends
  • 11.7. Teladoc Health
    • 11.7.1. Fundamental Analysis of Company Financials
      • 11.7.1.1. Insights from Balance Sheet
      • 11.7.1.2. Analysis of Financial Ratios
    • 11.7.2. Technical Analysis of Stock Price
      • 11.7.2.1. Historical Trends
      • 11.7.2.2. Recent Trends

Section IV: Business Risk Analysis

12. Risk Analysis of Public Companies

  • 12.1. Overview
  • 12.2. Business Risk Analysis
    • 12.2.1. Operations-related Risks
    • 12.2.2. Business-related Risks
    • 12.2.3. Product / Technology Risks
    • 12.2.4. Financial / Asset-related Risks
    • 12.2.5. Other Risks
  • 12.3. Concluding Remarks

Section V: Opportunity Analysis & Mapping Key Investor Exits

13. Market Forecast and Opportunity Analysis

  • 13.1. Overview and Methodology
  • 13.2. Overall Telehealth Market Size, 2021-2035
    • 13.2.1. Analysis by Key Market Segments
    • 13.2.2. Analysis by Geography
    • 13.2.3. Concluding Remarks

14. Investor Exits & Estimated Returns on Investment

  • 14.1. Outlook for Investors
  • 14.2. Publicly Disclosed Investor Exits
    • 14.2.1. Estimated Returns on Investment
  • 14.3. Concluding Remarks

15. Key Acquisition Targets

  • 15.1. Overview
  • 15.2. Analysis of Key Acquisition Targets
  • 15.3. Concluding Remarks

16. Appendices I: Tabulated Data

17. Appendices II: List of Companies & Organizations

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. 406 Ventures
  • 2. 14W
  • 3. 20/20 HealthCare Partners
  • 4. 415 Ventures
  • 5. 7wire Ventures
  • 6. 8VC
  • 7. A.Capital
  • 8. Aaron Patzer
  • 9. AB Kinnevik
  • 10. Abu Dhabi Investment Office
  • 11. Accel
  • 12. Accelerator
  • 13. Access Industries
  • 14. Acme Capital
  • 15. ACRA
  • 16. Acrew Capital
  • 17. Acrew Capital's Scout Fund
  • 18. Activant Capital
  • 19. Adam Balon
  • 20. Adamed
  • 21. Adaptive Healthcare Fund
  • 22. Add Health Media
  • 23. Affinity Capital Management
  • 24. Air Angels
  • 25. AirAngels
  • 26. AirTree Ventures
  • 27. Ajit Gunewardene
  • 28. ALES Global Japan
  • 29. Allianz X
  • 30. Ally Bridge Group
  • 31. Ally Bridge Group (ABG)
  • 32. Alma Mundi Fund
  • 33. Alma Mundi Ventures
  • 34. Alphabet's investment arm
  • 35. Altimeter Capital
  • 36. Alumni Ventures Group
  • 37. Amazon
  • 38. AME Cloud Ventures
  • 39. American Investment Holdings
  • 40. Amgen
  • 41. Amgen Ventures
  • 42. Amgen Ventures
  • 43. Amit Bhatia
  • 44. and Eliana Murillo
  • 45. and Fosun Pharma
  • 46. and New Capital Partners
  • 47. and others.
  • 48. and Skip Battle
  • 49. and Starbucks
  • 50. Andreessen Horowitz
  • 51. Anne Wojcicki
  • 52. Anshumani Ruddra
  • 53. Anthem Health
  • 54. Antonio Gracias
  • 55. Ardea Capital Partners
  • 56. Arizona Founders Fund
  • 57. Arthur Ventures
  • 58. Artis Ventures
  • 59. Ascension Ventures
  • 60. Asia Africa Investment & Consulting
  • 61. Asia Partners
  • 62. Aspect Ventures
  • 63. Atento Capital
  • 64. Athenahealth
  • 65. Athensmed
  • 66. Atlantic Labs
  • 67. Atomico
  • 68. Autonomous Ventures
  • 69. Avalon Ventures
  • 70. AWE Funds
  • 71. AXA Venture Partners (AVP)
  • 72. Axilor Ventures
  • 73. Baidu Ventures
  • 74. Baillie Gifford
  • 75. Bain Capital Ventures
  • 76. Bain Capital Ventures. Uprising
  • 77. Baring Vostok
  • 78. Barry Sternlicht
  • 79. Bascom Ventures
  • 80. Base10 Partners
  • 81. Battery Ventures
  • 82. Bayer
  • 83. BDC Capital
  • 84. Bessemer Venture Partners
  • 85. Bill Ackman
  • 86. Black Pearls VC
  • 87. Blackbird
  • 88. Blackbird Ventures
  • 89. Blue Cross Blue Shield of Massachusetts
  • 90. Blue Ivy Ventures
  • 91. Blue Venture Fund
  • 92. Blueprint Health
  • 93. BlueRun Ventures
  • 94. BOND
  • 95. Bootstrap Incubation
  • 96. Boston Millennia Partners
  • 97. BoxGroup
  • 98. BPEA
  • 99. Bracket Capital
  • 100. Breyer Capital
  • 101. Bridges Israel
  • 102. BrightEdge
  • 103. Brown Angel Group
  • 104. Burst Capital
  • 105. Caisse de dépôt et placement du Québec (CDPQ)
  • 106. California Health Care Foundation Innovation Fund
  • 107. Cambia Health Solutions
  • 108. Canaan Partners
  • 109. Canada Pension Plan Investment Board
  • 110. Canvas
  • 111. Canvas Ventures
  • 112. Capital Union Investments
  • 113. Cardinal Partners
  • 114. Casdin Capital
  • 115. CDPQ
  • 116. Centene
  • 117. Centre for Innovation Incubation and Entrepreneurship (CIIE)
  • 118. Cherif Habib
  • 119. Chris Burch
  • 120. CICC
  • 121. Cigna Ventures
  • 122. City Light Capital
  • 123. Claes Dinkelspiel
  • 124. Clark Valberg
  • 125. Clearvision Equity
  • 126. CMI Ventures
  • 127. Collaborative Fund
  • 128. Colle Capital Partners
  • 129. Colorado Impact Fund
  • 130. Comcast Ventures
  • 131. Company Ventures
  • 132. Compound Ventures
  • 133. Connect the Grey Investment Management
  • 134. Corisol Holding
  • 135. Corisol Holdings
  • 136. Correlation Ventures
  • 137. Cowen Private Investments
  • 138. Cox Enterprises
  • 139. CQRS Limited
  • 140. Creadev
  • 141. Creandum
  • 142. Creathor Ventures
  • 143. Crosscut Ventures
  • 144. CRV
  • 145. CSIRO's VC fund
  • 146. CU Healthcare Innovation Fund
  • 147. CU Healthcare Innovation Fund
  • 148. Cumberland VC
  • 149. D1 Capital Partners
  • 150. Daniel Gulati
  • 151. Dara Khosrowshahi
  • 152. David Ellison
  • 153. David H. Petraeus
  • 154. Debiopharm Innovation Fund
  • 155. Dedalus Group
  • 156. Deena Shakir
  • 157. Deerfield Management Company
  • 158. Define Ventures
  • 159. Demis Hassabis
  • 160. DFJ
  • 161. Digital Future
  • 162. Digital Health Ventures
  • 163. Dioko Health Ventures
  • 164. Dioko Health Ventures
  • 165. Discount Tech
  • 166. Dr. Jeremy Lim
  • 167. Dr. Mark Friedman
  • 168. Dr. Rushika Fernandopoulle
  • 169. Dragoneer Investment Group
  • 170. Dreamers Fund
  • 171. Drive Capital
  • 172. dRx Capital
  • 173. DRX Capital
  • 174. DST Global
  • 175. Dubai Angel Investors
  • 176. Dundee Venture Capital
  • 177. e.ventures
  • 178. Early Light Ventures
  • 179. EASME - EU Executive Agency for SMEs
  • 180. Echo Health
  • 181. Echo Health Ventures
  • 182. ECMC
  • 183. EDBI
  • 184. Eight Roads Ventures
  • 185. Emily Melton
  • 186. Emmett Partners
  • 187. Eniac Ventures
  • 188. Equity Venture Partners
  • 189. ERGO Fund
  • 190. Eric Schmidt's Innovation Endeavors
  • 191. ES Investor
  • 192. Esther Dyson
  • 193. Euclidean Capital
  • 194. European Commission
  • 195. Exponent
  • 196. F Cubed
  • 197. Faber Ventures
  • 198. Fairview Health Services
  • 199. Female Founders Fund
  • 200. Fidelity Management & Research
  • 201. Fidelity Management & Research Company
  • 202. FinSight Ventures
  • 203. FinX Capital
  • 204. First Ascent Ventures
  • 205. First Trust Capital Partners
  • 206. FirstMark Capital
  • 207. FirstTime.
  • 208. FJ Labs
  • 209. FLAG Capital Management
  • 210. Flashpoint Venture Capital
  • 211. Flint Capital
  • 212. Florian Jansen
  • 213. Fosun Pharma
  • 214. Founders Fund
  • 215. F-Prime Capital
  • 216. F-Prime Capital
  • 217. F-Prime Capital Partners
  • 218. Francisco Partners
  • 219. Freestyle Capital
  • 220. Frist Cressey Ventures
  • 221. Future Perfect Ventures
  • 222. Gaingels
  • 223. GAN
  • 224. GAN Ventures
  • 225. Gates Foundation
  • 226. GE Ventures
  • 227. General Atlantic
  • 228. General Catalyst
  • 229. Geoff Price
  • 230. George Ruan
  • 231. GGV Capital
  • 232. GlaxoSmithKline
  • 233. Global Voyager Fund
  • 234. Glynn Capital Management
  • 235. Goldman Sachs Investment Partners
  • 236. Goldman Sachs Merchant Banking Division
  • 237. Goldman Sachs' merchant banking
  • 238. Goodwater Capital
  • 239. Google Cloud
  • 240. Google Ventures
  • 241. Google's VC
  • 242. Gradient Ventures
  • 243. Grand Central Tech Ventures
  • 244. Great Oaks VC
  • 245. Great Oaks Venture Capital
  • 246. Green Innovations
  • 247. Greenspring Associates
  • 248. Groupe Arnault
  • 249. GSMA Ecosystem Accelerator
  • 250. GSR Ventures
  • 251. Guidewell
  • 252. GuideWell Mutual Holding Corporation
  • 253. GV
  • 254. GV
  • 255. Hacking Health Accelerator.
  • 256. Hambrecht Ducera Growth Ventures
  • 257. Harmony Partners
  • 258. Harri Tilev
  • 259. Hashtag One
  • 260. Hawke Ventures
  • 261. HBM Healthcare Investment
  • 262. HBM Healthcare Investments
  • 263. Headwater VC
  • 264. Health Catalyst Capital
  • 265. Health Velocity Capital
  • 266. HealthInvest Equity Partners
  • 267. HEALTHY VENTURES
  • 268. Henley Business Angels
  • 269. Heritage Medical Systems
  • 270. Heritage Provider Network
  • 271. Highline
  • 272. Highmark Ventures
  • 273. Hikma Ventures
  • 274. HIMAngel
  • 275. HLM Venture Partners
  • 276. HLM Ventures
  • 277. Holtzbrinck Ventures
  • 278. Horizon 2020 SME support program.
  • 279. Horizon BlueCross BlueShield of New Jersey
  • 280. Howard Jenkins
  • 281. Hoxton Ventures
  • 282. HPE Growth
  • 283. Huajin Fund
  • 284. Humana
  • 285. Hustle Fund
  • 286. Hyde Park Venture Partners
  • 287. Hyperplane Capital
  • 288. Icon Ventures
  • 289. IDFC Alternatives
  • 290. Idinvest Partners
  • 291. iGlobe Partners
  • 292. IHH Healthcare
  • 293. Illumina
  • 294. Illumina Ventures
  • 295. Impact Investments
  • 296. including Optum Ventures
  • 297. Index Ventures
  • 298. Indie.vc
  • 299. Inflection Capital
  • 300. Ingleside Investors
  • 301. Inkef Capital
  • 302. INKEF Capital
  • 303. InnoVen Capital
  • 304. InnoVision Capital
  • 305. Insight Partners
  • 306. Intel Capital
  • 307. International Finance Corporation (IFC)
  • 308. InvAscent
  • 309. Inventus Capital
  • 310. IRA Capital
  • 311. Israeli Innovation Authority
  • 312. Ithmar Capital Partners
  • 313. J.P. Morgan
  • 314. Jackson Square Ventures
  • 315. JAFCO Asia Fund
  • 316. Jafco Ventures
  • 317. Jamie McCourt
  • 318. Jason Calacanis
  • 319. Jawed Karim
  • 320. Jeff Weiner
  • 321. Jefferson Health System
  • 322. Jeremy Andrus
  • 323. Jeremy Yap
  • 324. Jerry Yang
  • 325. Jim Foreman
  • 326. John Simon
  • 327. Jon Wright
  • 328. Jonathan Bush
  • 329. June Fund
  • 330. Justin Kan
  • 331. Kae Capital
  • 332. Kae Capital
  • 333. Kaiser Permanente Ventures
  • 334. Kaiser Permanente Ventures and Illumina Ventures
  • 335. Kamet Capital
  • 336. Kamet Capital Partners
  • 337. Ken Goulet
  • 338. Ken Griffin
  • 339. Kenneth Griffin
  • 340. Kevin Hill
  • 341. Kevin Scott
  • 342. Khosla Ventures
  • 343. Khosla Ventures
  • 344. Khosla Ventures.
  • 345. Kickstart Seed Fund
  • 346. Kim Hammonds
  • 347. Kima Ventures
  • 348. Kinnevik
  • 349. Kleiner Perkins
  • 350. Kleiner Perkins Caufield & Byers
  • 351. Kleiner Perkins Caufield and Byers
  • 352. Kustaa Piha
  • 353. L Catterton
  • 354. LabCorp
  • 355. Lachy Groom
  • 356. Lanka Orix Leasing Company
  • 357. Lead Edge Capital
  • 358. Len Blavatnik's global investment group
  • 359. Leonard Lynch
  • 360. Lerer Hippeau
  • 361. Lerer Hippeau Ventures
  • 362. Lerer Ventures
  • 363. LetsVenture
  • 364. LifeSci Ventures
  • 365. Lightspeed Venture Partners
  • 366. Lightspeed Venture Partnersl
  • 367. Lightspeed Ventures
  • 368. LionBird
  • 369. Lionel Richie
  • 370. Liquid 2 Ventures
  • 371. LLC
  • 372. Lori Goler
  • 373. LPs Bill
  • 374. LRVHealth
  • 375. Lux Capital
  • 376. Lux Capital
  • 377. M25
  • 378. M25 Group
  • 379. MadhanKumar Madathupalayam
  • 380. MAF Mauritius
  • 381. Main Sequence Ventures
  • 382. Manatt Venture Fund
  • 383. March Capital
  • 384. Mark Leslie
  • 385. Martin Ventures
  • 386. Matrix Partners
  • 387. Matt Mullenweg
  • 388. Maven Ventures
  • 389. Maverick Capital Ventures
  • 390. Maverick Ventures
  • 391. Mayfield Fund
  • 392. Maynard Webb
  • 393. Medical Angels investment group
  • 394. Mellon and QuestMark Partners
  • 395. MemorialCare Innovation Fund (MCIF)
  • 396. Merck Global Health Innovation Fund
  • 397. Mercury Fund
  • 398. Metamorphic Ventures
  • 399. Metsola Ventures
  • 400. Michael Stoppelman
  • 401. Microsoft
  • 402. Microsoft Ventures
  • 403. Mike Silagadze
  • 404. Mike Wortsman
  • 405. Mikhail Sokolov
  • 406. Mikhail Tsyferov
  • 407. Milliways Ventures
  • 408. Mindy Kaling
  • 409. MK Capital
  • 410. Mohr Davidow Ventures
  • 411. Montage Ventures
  • 412. Morado Ventures
  • 413. Morningside Ventures
  • 414. MPM Capital
  • 415. MPOF Mauritius
  • 416. Mubadala Ventures
  • 417. Mustafa Suleyman
  • 418. Nat Turner
  • 419. Natalie Portman
  • 420. Nathan and Sonia Baschez
  • 421. Nathan Kirsh
  • 422. Natie Kirsh
  • 423. National Bank of Canada
  • 424. National Center for Research and Development
  • 425. National Institutes of Health
  • 426. New Capital Partners and Trident Capital
  • 427. New Enterprise Associates
  • 428. New Enterprise Association
  • 429. new investors Blue Cloud Ventures
  • 430. New York Angels
  • 431. NewFlight
  • 432. NewView Capital
  • 433. NEXT Canada
  • 434. Next Ventures
  • 435. Next Wave Impact Fund
  • 436. NextView Ventures
  • 437. NGP Capital
  • 438. NGP Capital.
  • 439. Nikhil Krishnan
  • 440. Nokia Growth
  • 441. Norwest Venture Partners
  • 442. Norwest Venture Partners
  • 443. Norwest Venture Partners
  • 444. Notation Capital
  • 445. Novartis
  • 446. Novartis Venture Fund
  • 447. Novo Holdings
  • 448. Novotech Health Holdings
  • 449. Oak HC/FT
  • 450. Obvious Ventures
  • 451. Obvious Ventures
  • 452. Olive Tree Ventures
  • 453. Omidyar Network
  • 454. Omphalos Venture Partners
  • 455. Omphalos Ventures
  • 456. Ontario Centres of Excellence
  • 457. Ontario Teachers' Pension Plan
  • 458. operational VC
  • 459. Optum Ventures. Centene Corporation
  • 460. Orbimed
  • 461. OrbiMed Israel Partners
  • 462. ORIX Growth Capital
  • 463. ORIX Healthcare Capital
  • 464. Orpah Winfrey
  • 465. Owl Ventures
  • 466. Oxeon Investments
  • 467. Palm Drive Capital
  • 468. Parkview Investment Advisors
  • 469. Patrick J. Kennedy.
  • 470. Patrick Spain
  • 471. Paul Buchheit
  • 472. Paul Jaobs
  • 473. Pavilion Capital
  • 474. Pelion Venture Partners
  • 475. Per Båtelson
  • 476. Perceptive Advisors
  • 477. Peterson Ventures
  • 478. Philips
  • 479. Phoenix Ventures
  • 480. physician-led MEDA Angels
  • 481. PinPoint Ventures
  • 482. PKO VC
  • 483. Portag3 Ventures
  • 484. PPD
  • 485. PPD
  • 486. PPD
  • 487. Precursor Ventures
  • 488. Prime Capital
  • 489. Princeville Global
  • 490. Pritzker Capital
  • 491. Pritzker Group Venture Capital
  • 492. Prodeko Ventures
  • 493. Programa
  • 494. Project A
  • 495. Project A Ventures
  • 496. Project A.
  • 497. Qualcomm Ventures
  • 498. Questa Capital
  • 499. Questa Capital Management
  • 500. Qumra Capital
  • 501. Qura
  • 502. Qure
  • 503. Rand Capital
  • 504. Randor
  • 505. Reaktor Ventures
  • 506. Real Ventures
  • 507. Rebright Partners
  • 508. Redmile Group
  • 509. Redwood Global Healthcare Fund
  • 510. Reese Witherspoon
  • 511. Revolution Growth
  • 512. Richard Park
  • 513. Richard Reed
  • 514. Ridgeview Asset Management
  • 515. Right Side Capital Management
  • 516. RLJ Equity Partners
  • 517. Roche Venture Fund
  • 518. Rockies Venture Club
  • 519. Rockies Venture Fund
  • 520. Rohini Pandhi
  • 521. Rohit M.A.
  • 522. Romulus Capital
  • 523. Rucker Park Capital
  • 524. Rushan Venture Capital
  • 525. Rushika Fernandopulle
  • 526. Rustic Canyon Partners
  • 527. Safeguard Scientifics
  • 528. Sami Inkinen
  • 529. Samsung Catalyst Fund
  • 530. Sand Hill Angels
  • 531. Sanofi
  • 532. Sanofi Ventures
  • 533. Sanofi-Genzyme BioVentures
  • 534. Sapphire Ventures
  • 535. Saudi Arabia's Public Investment Fund
  • 536. Saudi's Athaal Group
  • 537. SBK Tech Ventures
  • 538. Scale AI
  • 539. SEI Ventures
  • 540. Sequoia
  • 541. Sequoia Capital
  • 542. Sequoia Capital India
  • 543. Seraph Group
  • 544. Sergey Brin
  • 545. Service Provider Capital
  • 546. Seyen Capital
  • 547. Shakopee
  • 548. Shasta Ventures
  • 549. Shasta Ventures
  • 550. Shea Ventures
  • 551. Sherpa Ventures
  • 552. Sierra Ventures
  • 553. SignalFire
  • 554. Signia Venture Partners
  • 555. Silicon Valley Bank
  • 556. Silver Lake Waterman
  • 557. Silverton Partners
  • 558. Sir Richard Branson
  • 559. Slauson & Co.
  • 560. Slow Ventures
  • 561. Soft Bank
  • 562. Softbank
  • 563. SoftBank
  • 564. Sogou
  • 565. Soma Capital
  • 566. Sound Ventures
  • 567. Spark Capital
  • 568. SpeedUp Venture Capital Group
  • 569. Spring Lake Equity Partners
  • 570. Spring Mountain Capital
  • 571. Spring Mountain Capital
  • 572. Sputnik ATX
  • 573. SputnikATX Ventures
  • 574. Square Peg
  • 575. Stage 2 Capital
  • 576. Stanford Health Care
  • 577. Starting Line
  • 578. Startup Health
  • 579. Sterling's capital
  • 580. Steve Shulman
  • 581. Steven Cohen
  • 582. Storm Ventures
  • 583. Streamlined Ventures
  • 584. Streamlined Ventures.
  • 585. Streamlined Ventures.
  • 586. Stride Ventures
  • 587. Structure Capital
  • 588. Summation Health Ventures
  • 589. Sun Life
  • 590. Susan Lyne
  • 591. SV Angel
  • 592. Takeda
  • 593. Taru Kapoor
  • 594. Tata Group
  • 595. TDJ Pitango Ventures
  • 596. TEAMFund LP
  • 597. Tech Council Venture
  • 598. Techstars
  • 599. Teladoc Health
  • 600. Tenaya Capital
  • 601. Tencent
  • 602. Tesi
  • 603. Teuza
  • 604. The American Cancer Society
  • 605. the Colorado Impact Fund
  • 606. The Council
  • 607. The Daube Family office
  • 608. The Family
  • 609. The Jump Fund
  • 610. The Living Fund.
  • 611. The Mayfield Fund
  • 612. The Valley Fund
  • 613. The Cooperative Research Centre Project
  • 614. TheTime
  • 615. Thomas Lehrman
  • 616. Three Fields Capital
  • 617. Three Leaf Ventures
  • 618. Tiger Global and Qumra Capital
  • 619. TKS I
  • 620. Tobias Lütke
  • 621. Todd Cozzens
  • 622. Tom Meredith
  • 623. Tony Fadell's Future Shape
  • 624. Town Hall Ventures
  • 625. Transformation Capital
  • 626. Trans-Pacific Technology Fund
  • 627. Trident Capital
  • 628. TrueSight Ventures
  • 629. Trustbridge
  • 630. TT Capital Partners
  • 631. Tull Investment Group
  • 632. Tusk Venture Partners
  • 633. Tusk Venture Partners
  • 634. TVC Capital
  • 635. Two Sigma Ventures
  • 636. Two Sigma Ventures
  • 637. TYLT Labs
  • 638. UC San Francisco
  • 639. Union Square Ventures
  • 640. Uniqa Ventures
  • 641. Unitus Ventures
  • 642. University Growth Fund
  • 643. Unpopular Ventures
  • 644. Unseen Capital
  • 645. Urban Capital Network
  • 646. Vega Ventures
  • 647. Velocity
  • 648. Venrock
  • 649. Venture Catalysts
  • 650. Venture Founders
  • 651. Vertical Venture Partner
  • 652. Vesalius Biocapital
  • 653. Vesalius Biocapital and Faber
  • 654. Vesalius Biocapital III
  • 655. Vida Ventures
  • 656. Vir Kashyap
  • 657. VMG Partners
  • 658. VNV Global
  • 659. Vostok New Ventures
  • 660. W23
  • 661. Walgreens
  • 662. Walgreens Boots Alliance
  • 663. Wallenberg Foundation
  • 664. Walter Capital National Bank of Canada
  • 665. Walter Financial
  • 666. Walter Ventures
  • 667. Wanxiang America Corporation
  • 668. Waterline Ventures
  • 669. Waypoint Capital Partners
  • 670. Webb Investment Network
  • 671. Wefunder
  • 672. WELL Health Technologies
  • 673. Westcap
  • 674. Western Technology Investment
  • 675. WestTech Ventures
  • 676. White Star Capital
  • 677. Whittier Ventures
  • 678. Wild Ventures
  • 679. William Tunstall-Pedoe
  • 680. Wittington Ventures
  • 681. Workday Ventures
  • 682. World Innovation Lab Venrock
  • 683. WTI and other unnamed individual investors
  • 684. WuXi Healthcare Ventures
  • 685. Xfund
  • 686. Y Combinator
  • 687. Yahoo founder Jerry Yang's AME Cloud Ventures
  • 688. Yandex
  • 689. Yuri Milner
  • 690. Zac Weinberg
  • 691. Zaffre Investments
  • 692. Ziegler LinkAge Fund